50 results about "Diad" patented technology

The invention relates to novel adhesive alpha-olefin inter-polymers which are largely amorphous and have a rheological behavior that makes them suitable for adhesive use, both without and with minimized amounts of tackifying resins. Specifically, the invention poly-alpha olefin inter-polymer may be composed of A) from 60 to 94 mol % of units derived from one alpha mono-olefin having from 3 to 6 carbon atoms and B) from 6 to 40 mol % of units derived from one or more other mono-olefins having from 4 to 10 carbon atoms and at least one carbon atom more than A); and C) optionally from 0 to 10 mol % of units derived from another copolymerizable unsaturated hydrocarbon, different from A) and B); the diad distribution of component A in the polymer as determined by <13>C NMR as described herein showing a ratio of experimentally determined diad distribution over the calculated Bernoullian diad distribution of less than 1.07; and the storage modulus G' of said polymer, determined upon cooling as described herein, intersecting a value of 3.10<5 >Pa at a temperature of less than 85° C. The invention also describes polymerization processes suitable for the manufacture of these adhesive alpha-olefin inter-polymers.

The invention provides a preparation method of porphyrin photosensitizer and anticarcinogen diad, relates to a preparation method of the diad and solves the technical problems that the porphyrin photosensitizers cannot kill all cancer cells under the light irradiation, the targeting of the anticarcinogen is insufficient, and toxic or side effects are generated. The method comprises the following steps of: 1, preparing midbodies; and 2, preparing the porphyrin photosensitizer and anticarcinogen diad. Because porphyrin and the metal complex compounds thereof have special affinity on the cancer cells, the photosensitizers of 4-hydroxyphenyl porphyrin and anticarcinogen are prepared into the diad, the affinity of the porphyrin on the cancer cells is utilized, so the targeting of the anticarcinogen can be improved, the anti-cancer capability is improved, and in addition, the toxic or side effect is reduced. The anti-cancer effect of the anticarcinogen overcomes the defect of insufficient anti-cancer capability of the porphyrin photosensitizer. Under the conditions of light illumination and dark light, two different anti-cancer mechanisms realize the cooperative effect, the advantage complementation of the anti-cancer effects of the two compounds is realized, the toxic or side effects are reduced under the use condition of the same quantity, and the anti-cancer capability is improved.

A novel olefin-based polymer has excellent thermal resistance, as well as excellent balance among various properties. The olefin-based polymer is an olefin-based polymer comprising 50 to 100% by weight of a constituent unit derived from 4-methyl-1-pentene, and 0 to 50% by weight of a constituent unit derived from at least one olefin selected from olefins having 2 to 20 carbon atoms except 4-methyl-1-pentene, and having the following properties: i) the diad isotacticity is 70% or greater, ii) the ratio (Mw / Mn) of the weight average molecular weight (Mw) to the number average molecular weight (Mn) as measured by gel permeation chromatography (GPC) is in the range of 1.0 to 3.5, and iii) the intrinsic viscosity [η] is 0.5 (dl / g) or greater.

The invention discloses a fusion protein of a thrombopoietin mimetic peptide (TMP) diad and a human serum albumin (HSA), and a preparation method and application thereof. The fusion protein comprises one HSA and two TMPs, wherein the HSA is positioned at the N-terminal of the fusion protein, and the two TMP sequences are connected in series to form a diad which is positioned at the C-terminal of the fusion protein; or the HSA is positioned at the C-terminal of the fusion protein, and the two TMP sequences are connected in series to form a diad which is positioned at the N-terminal of the fusion protein. Connecting peptides are arranged between the HSA and the TMP diad as well as between the two TMPs. The fusion protein has a characteristic of obviously promoting thrombocytopoiesis, has a long half life in vivo and can be used for the preparation of medicaments for treating multiple primary or secondary thrombocytopenia and other diseases.

A novel olefin-based polymer has excellent thermal resistance, as well as excellent balance among various properties. The olefin-based polymer is an olefin-based polymer comprising 50 to 100% by weight of a constituent unit derived from 4-methyl-1-pentene, and 0 to 50% by weight of a constituent unit derived from at least one olefin selected from olefins having 2 to 20 carbon atoms except 4-methyl-1-pentene, and having the following properties: i) the diad isotacticity is 70% or greater, ii) the ratio (Mw / Mn) of the weight average molecular weight (Mw) to the number average molecular weight (Mn) as measured by gel permeation chromatography (GPC) is in the range of 1.0 to 3.5, and iii) the intrinsic viscosity [η] is 0.5 (dl / g) or greater.

The invention discloses preparation and application of a dimerized thrombopoietin (TPO) mimic peptide TMP diad-human serum albumin fusion protein. The fusion protein contains an HAS and two TPO mimic peptides which are connected through a linkage oligopeptide and a dimerization domain so as to ensure the fusion protein is dimerized correctly when expression. The two TPO mimic peptides can be connected with N terminal or C terminal of HAS. The dimerized HAS protein carrier and the TPO mimic peptide fusion protein provided by the invention have a significant activity of promoting thrombopoiesis in vivo and can be applied in preparation of drugs for treating primary and secondary thrombocytopenia diseases.

The present invention is generally directed to a method of capturing an identity of a party asserting an identity in a transaction receiving goods or services, including: providing a device to a signing party to receive the signature; recording a video of the signing party providing a signature on the device; and associating in a data store the video and the signature. Other aspects of the present invention may include an application or program which, when executed by one or more processors in a mobile phone, tablet computer, or delivery information acquisition device (“DIAD”), cause the performance of the steps: recording an image of a party asserting an identity; recording a video of the signing party providing a signature; capturing the time and date; determining the location; and associating in a data store the image, video, signature, time and date, and location.

The invention provides a salvianolic acid A salt complex. The salvianolic acid A salt complex is prepared from diad salvianolic acid A and a positive ion, the salvianolic acid A salt complex has the chemical construction (being defined as in the specification); and the salvianolic acid A salt complex has the pharmacological activity of anti-myocardial ischemia treating, anti-myocardial ischemia reperfusion injury treating, and platelet aggregation inhibition, and can be applied to preparation of medicines with the related curative effect. The preparation method of the salvianolic acid A salt complex is simple, easy to produce, and more stable relative to the salvianolic acid A.

The invention belongs to the field of genetic engineering pharmacy, relates to a fusion protein of thrombopoietin and a preparation method and an application thereof, in particular to the fusion protein of a human serum albumin (HSA) and a yeast-preferred codon-encoded thrombopoietin mimetic peptide (TMP) diad and the preparation method and the application thereof. The fusion protein comprises theHSA molecule and the yeast-preferred codon-encoded TMP diad, the fusion protein can be stably expressed at a high level in yeast, and can be applied to industrial production; at the same time, the fusion protein has a characteristic of promoting thrombopoiesis significantly, has a long half-life in the human body, and can be used for preparing a medicine for treating various diseases such as primary or secondary thrombocytopenia.

The invention provides a preparation method of porphyrin photosensitizer and anticarcinogen diad, relates to a preparation method of the diad and solves the technical problems that the porphyrin photosensitizers cannot kill all cancer cells under the light irradiation, the targeting of the anticarcinogen is insufficient, and toxic or side effects are generated. The method comprises the following steps of: 1, preparing midbodies; and 2, preparing the porphyrin photosensitizer and anticarcinogen diad. Because porphyrin and the metal complex compounds thereof have special affinity on the cancer cells, the photosensitizers of 4-hydroxyphenyl porphyrin and anticarcinogen are prepared into the diad, the affinity of the porphyrin on the cancer cells is utilized, so the targeting of the anticarcinogen can be improved, the anti-cancer capability is improved, and in addition, the toxic or side effect is reduced. The anti-cancer effect of the anticarcinogen overcomes the defect of insufficient anti-cancer capability of the porphyrin photosensitizer. Under the conditions of light illumination and dark light, two different anti-cancer mechanisms realize the cooperative effect, the advantage complementation of the anti-cancer effects of the two compounds is realized, the toxic or side effects are reduced under the use condition of the same quantity, and the anti-cancer capability is improved.

A sealing member to be used for sealing a constituent member of a fuel cell is provided, the sealing member including a cross-linked product of a rubber composition, in which the rubber composition contains the following components (A) and (B). With this, rubber elasticity is maintained without being lost even under extremely low temperature conditions, and in the case where the sealing member is used in a fuel cell sealed body, an excellent sealing property is exhibited. (A) a rubber component including at least one of an ethylene-propylene rubber or ethylene-propylene-diene rubber having a ratio of ethylene-ethylene diad distribution of at most 29 mol %. (B) a cross-linking agent including an organic peroxide.

The invention relates to a fusion protein of human parathyrine (1-34) diad and human seralbumin and a preparation technology thereof, belonging to the technical field of long lasting recombinant fusion protein. The fusion protein comprises the first region of the diad which has at least 85% homologous sequence with the human parathyrine (1-34) and the second region which has at least 85% homologous sequence with the human seralbumin. Using overlapping PCR technology twice, firstly two h PTH (1-34) are spliced to obtain the diad, and secondly the diad and H AS are spliced together without any connecting peptide. The fusion protein can replace, delete or add in respective amino acid residue under the premise that the feature of the fusion protein is not changed, prominently extends the half life period in human body based on the condition that the function of the human parathyrine for activating receptor and irritating bone remodeling is retained, and is the medicinal fusion protein which is used for curing osteoporosis and has good perspective in the pharmaceutical field.

Disclosed is a tape base exhibiting excellent oil resistance, while having flexibility, cuttability by hand and heat resistance in a balanced manner. Also disclosed is an adhesive tape using the tape base. Specifically disclosed is a tape base containing an ethylene-aromatic vinyl compound copolymer having an isotactic tacticity. In the copolymer structure of the ethylene-aromatic vinyl compound copolymer, the isotactic diad fraction m of Ph (aromatic group) in the alternating structure of ethylene and the aromatic vinyl compound represented by the formula (1) below is preferably more than 0.75. (1) (In the formula, Ph represents an aromaticgroup, and xa represents the number of repeating units, which is an integer of not less than 2).

Systems and methods for facilitating secured loan transactions are provided. Drivers of a fleet of parcel delivery vehicles associated with a particular common carrier are used to pick up collateral from a borrower to secure a loan. A driver visits the borrower's address as part of executing parcel delivery transactions to pick up the collateral. The driver may verify the borrower's identity and the validity of the collateral when receiving the collateral. An indication of the receipt of the borrower's collateral is provided to a system accessible by a lending facilitator, such as via the driver's DIAD. The indication can be used by the peer-to-peer lending facilitator to determine a level of risk associated with entering into a loan transaction with the borrower and / or an interest rate for the loan. In some cases, the collateral is delivered to a third party escrow service.